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ARTICLE
Synthetic miRNAs induce dual arboviral-resistance
phenotypes in the vector mosquito Aedes aegypti
Pei-Shi Yen1, Anthony James2, Jian-Chiuan Li3, Chun-Hong Chen3 & Anna-Bella Failloux 1
Mosquito-borne arboviruses are responsible for recent dengue, chikungunya, and Zika pan-
demics. The yellow-fever mosquito, Aedes aegypti, plays an important role in the transmission
of all three viruses. We developed a miRNA-based approach that results in a dual resistance
phenotype in mosquitoes to dengue serotype 3 (DENV-3) and chikungunya (CHIKV) viruses.
The target viruses are from two distinct arboviral families and the antiviral mechanism is
designed to function through the endogenous miRNA pathway in infected mosquitoes.
Challenge experiments showed reductions in viral transmission efﬁciency of transgenic
mosquitoes. Several components of mosquito ﬁtness were examined, and transgenic
mosquitoes with the PUb promoter showed minor ﬁtness costs at all developing stages.
Further development of these strains with gene editing tools could make them candidates for
releases in population replacement strategies for sustainable control of multiple arbovirus
diseases.
DOI: 10.1038/s42003-017-0011-5 OPEN
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Dengue and chikungunya are two major arboviral diseasesthat have emerged as global threats in the past decades.Approximately 390 million people are infected annually
with dengue and over 50% of the world’s population live under
the risk of infection, draining annually an estimated $40 billion
for health-care spending and lost productivity in affected coun-
tries1. Compared to dengue, chikungunya has a lesser impact on
public health and had been a neglected tropical disease until the
2005 outbreak in La Réunion Island, when one-third of the
population was affected. Since then, there have been several
chikungunya outbreaks worldwide including in Southeast and
East Asia, Central Africa, South Paciﬁc Islands, and lately in Latin
America and the Caribbean2. Many imported cases have been
reported in Europe and North America raising the risk of local
transmission. Autochthonous cases of dengue were recorded in
Croatia3, France4,5, and Madeira6, while chikungunya has
appeared in Italy7 and France8,9.
Dengue virus (DENV) and chikungunya virus (CHIKV) co-
circulate in several tropical areas and co-infections in human are
frequently reported10–22. The viruses belong to two distinct
families but share the same mosquito vectors, Aedes species.
Mosquitoes can acquire DENV and CHIKV simultaneously after
feeding on a co-infected patient or after two consecutive blood
meals on viremic hosts23. Co-infected mosquitoes can transmit
concomitantly DENV and CHIKV to subsequent hosts24, and this
is likely to cause more severe symptoms than mono-infections10,25.
DENV-3 is the fastest spreading DENV serotype in the past two
decades26. Because a licensed tetravalent dengue vaccine is still not
available27,28, novel vector control strategies are needed to prevent
virus transmission between mosquitoes and hosts. Furthermore,
while vaccination would greatly reduce urban transmission, enzootic
circulation of arboviruses carries the risk of mutation accumulation
and spillover infections that would not be impeded29–31. Eliminating
both CHIKV and DENV-3 viruses in mosquito vectors would
reduce the burden on population health, particularly for countries
already under stress in their health-care system.
While most arboviruses can induce signiﬁcant morbidity and/or
mortality in some vertebrate hosts, infections of mosquito vectors
are generally considered non-pathogenic32. However, interactions
between the replicating virus and the mosquito immune defense
system may inﬂuence subsequent viral dissemination and trans-
mission. Considerable progress has been achieved in under-
standing the innate defenses of the mosquito against arboviruses.
Among them, RNA interference (RNAi) has been shown to be a
major innate response of mosquitoes against arboviruses. Knock-
down experiments targeting RNAi components such as Dcr2,
R2D2, and Ago2 in Aedes show increased viral loads or decreased
extrinsic incubation periods in mosquitoes33. Furthermore, virus
replication is suppressible in cultured mosquito cell lines expres-
sing long double-stranded RNA (dsRNA) molecules designed to
target the viral genome34. RNAi-based, virus-resistant mosquitoes
were developed in which transgenes comprising long dsRNAs
targeting DENV-2 under the control of a blood meal-inducible
gene promoter were able to confer a strong serotype-speciﬁc, virus-
resistance phenotype35–37. According to the species-conserved
miRNA processing pathway, the miRNA precursors (pri-miRNA)
are processed into ~70 nt hairpins by Drosha in the nucleus, which
is followed by exporting into the cytoplasm by Exportin5. In the
cytoplasm, the hairpins are cleaved into ~22 nt miRNA duplexes
by Dicer-1, which are then loaded into Ago-1 or Ago-2 proteins in
miRNA-induced silencing complexes (miRISCs) according to their
different structure properties38–40. By recognizing the com-
plementary sequence of the target RNA, miRISCs execute silencing
through RNA degradation, translational inhibition or both41,42.
Here we report the ﬁrst miRNA-based genetically engineered
mosquitoes, to our knowledge, that are refractory to DENV-3 and
CHIKV simultaneously. In addition, we show some ﬁtness costs
resulting from the transgenes, but anticipate that could be miti-
gated with additional modiﬁcations to the transgenes and their
insertion sites.
Results
Constructing the artiﬁcial antiviral miRNA. Two consensus
sequences of DENV-3 and CHIKV were deﬁned from 356 and 32
isolates, respectively, of each virus (Supplementary Data 1). Four
regions from DENV-3 and six from CHIKV were selected as the
targets of antiviral miRNAs on the basis of their sequence cov-
erage and targeted regions (Fig. 1). Corresponding miRNAs were
designed and cloned in tandem to make compound anti-viral
effector genes. The sequence coverages of the anti-DENV-3
miRNAs to the viruses used to generate the consensus sequence
range from 96.6% to 98.6%, and the targeted genes encode the
non-structural proteins, NS2B, NS3, and NS5. The anti-CHIKV
miRNAs have 96.9–100% identity to the viruses used to generate
the consensus sequence, and the targeted genes encode the non-
structural proteins, NSP1, NSP2, NSP3-4, NSP4, and the struc-
tural proteins E2, and E1 (Supplementary Table 1). In addition, to
verify if any miRNA off-target effect might be caused by the
synthetic antiviral miRNAs, all the sequences of each antiviral
miRNA were examined by the miRNA off-target effect prediction
software Genome-wide Enrichment of Seed Sequence matches
(GESS)43, including the passenger strands of each antiviral
miRNA; no statistically signiﬁcant interaction was identiﬁed
against any transcript of Ae. aegypti. All antiviral miRNA clusters
were constructed to place them under either the Aedes Poly-
Ubiquitin (AePUB) or Aedes Carboxypeptidase A (AeCPA) gene
promoters to elicit constitutive or blood meal-inducible, midgut-
speciﬁc expression of the effector molecules (Fig. 1).
Generation of transgenic mosquitoes. A Class II TE mariner
MosI system44 was used to generate transgenic mosquito lines by
microinjection in four separate experiments mixtures of the
donor plasmids, pMosI_AePUb>4miR:D3 (4miR:D3), pMo-
sI_AePUb>6miR:CHIKV (6miR:Chik), pMosI_AePUb>10miR:
D3+CHIKV (AePUb>10miR), and pMosI_AeCPA>10miR:D3
+CHIKV (AeCPA>10miR), with the transposase expressing
helper plasmid pKhsp82MOS. A total of 432, 595, 310, and 355
embryos were injected with each donor plasmid, and of these,
151, 153, 141, and 62, developed into adults. Following out-
crossing of G1 adults, a total of 1, 5, 3, and 5 lines, respectively,
were obtained from each crossing family (Supplementary
Table 2). Homozygous lines were generated by screening inter-
crossed families in which progeny were 100% reporter-positive
for two generations. The copy number of transgenic cassettes in
mosquito chromosomes was conﬁrmed by Southern blot analysis
using restriction enzymes that have no or only a single cutting site
within the transgene and 32P-labeled probes complementary to
the 10 miRNA cluster region. The results indicate that both
mosquito lines contain only a single copy of the transgene cassette
in a different locus in the genome (Supplementary Figure 1).
Expression of artiﬁcial miRNAs. Signals conﬁrming the expres-
sion of anti-CHIKV-4 and anti-DENV3-1 were detected by miRNA
qPCR analyses of female midguts and carcasses prepared from
tissues collected 0 and 24 h post blood meal (PBM; Fig. 2a, Sup-
plementary Figure 2). The mature miRNAs were polyadenylated,
followed by reverse transcription with poly(A)-adapter primer for
synthesizing an adapter-linked miRNA complementary DNA
(miRNA cDNA). With the miRNA-speciﬁc and adapter primers
(Supplementary Table 3), the mature miRNA can be detected by
qPCR analysis. The antiviral miRNAs of AePUb>10miR
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Fig. 1 Schematic of the artiﬁcial antiviral miRNA. a Target genes. b Expression cassettes. Based on mariner transposon system, the ubiquitous and midgut-
speciﬁc induction promoters were used for expressing the downstream synthetic miRNAs. AeCPA/PUb promoter, Ae. aegypti carboxypeptidase A/
PolyUbiquitin promoter; 4miR:DENV-3, anti DENV-3 miRNA cluster for four anti-DENV-3 miRNAs; 6miR:CHIKV, anti CHIKV miRNA cluster for six anti-
CHIKV miRNAs; 10miR:DENV-3+CHIKV, anti DENV-3/CHIKV miRNA cluster for four for DENV-3 and six for CHIKV
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Fig. 2 Detection of artiﬁcial antiviral miRNAs. a In midgut and carcass. b In salivary glands. Total RNA were isolated from mosquito midguts and carcasses
dissected at 0 and 24 h post blood meal, whereas the RNA of salivary glands were extracted from the mosquitoes co-challenged with CHIKV and DENV-3
at 0, 1, and 6 days after infection. Reverse transcription and qPCR were conducted as described in materials and methods. anti-CHIKV_6-4, the fourth anti-
CHIKV miRNA; anti-DENV-3_4-1, the ﬁrst anti-DENV-3 miRNA. Data were normalized to normalized values of aae-miR-1, and presented in relative
expression levels to aae-miR-1. Each sample corresponds to two replicates (2 × 12 mosquitoes)
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mosquitoes were detectable in the midgut and carcass, and a slightly
increased expression level was observed 24 h PBM. As the AeCPA
promoter is reported to be active in the midgut and salivary
glands45, the antiviral miRNAs was detected in the midgut and
carcass of AeCPA>10miR mosquitoes, and the expression levels
were increased 24 h PBM. The two antiviral miRNAs were also
detected from the samples of female salivary glands at day 0, 1, and
6 after receiving a viremic blood meal; the results show that both
antiviral miRNAs remain detectable in the salivary glands even at
day 6 after virus challenge (Fig. 2b, Supplementary Figure 2). We
interpret these data to indicate that the expression of the antiviral
miRNAs in the midgut, carcass and salivary glands, remains
inducible after receiving a blood meal.
Impacts of transgene on life-table parameters. A number of life-
table parameters that might be expected to affect ﬁtness were
evaluated. These include larval development time, larval/pupal
mortality, adult lifespan, sex ratio, and male mating competi-
tiveness (Table 1).
In our rearing conditions, wild-type (Orlando) mosquitoes
needed an average of 6.43± 0.03 (males) and 7.02± 0.05
(females) days for development from ﬁrst instar larvae to pupae,
while AePUb>10miR mosquitoes had development times of 6.12
± 0.03 (males) and 6.29± 0.03 (females) days, and AeCPA>10-
miR had 6.7± 0.04 and 6.87± 0.05 days for males and females,
respectively (Kruskal–Wallis test: p< 10−4 (males), p< 10−4
(females)). The larval mortality rate was 4.40± 0.86% and
16.90± 2.02% for AePUb> 10miR and AeCPA>10miR mosqui-
toes, respectively, and these latter were signiﬁcantly higher than
wild-type Orlando mosquitoes at 1.88± 0.56% (Fisher’s exact test:
p< 10−4). As for the pupal mortality, AeCPA>10miR mosquitoes
had a signiﬁcantly higher pupal mortality rate (Fisher’s exact test:
p< 10−4), 7.75%, compared to AePUb>10miR and wild-type
Orlando, 2.0% and 2.83%, respectively. The adult life spans were
also analyzed. The mean survival times of AePUb>10miR male
and female adults were 36.9± 11.75 and 41.78± 14.91 days,
respectively, which are not signiﬁcantly different than 39.51±
11.58 and 44.32± 14.23 days for wild-type Orlando mosquitoes
(Kruskal–Wallis test: p = 0.07). However, AeCPA> 10miR mos-
quitoes had shorter survival times with means of 23.61± 10.00
and 28.15± 12.83 days for males and females, respectively,
signiﬁcantly shorter than wild-type Orlando mosquitoes
(Kruskal–Wallis test: p< 10−4). AeCPA>10miR mosquitoes have
a signiﬁcantly lower survival rate than the two other strains (log
rank test: p< 0.05) (Fig. 3a and b). Among these adult
mosquitoes, the percent of female AeCPA>10miR mosquitoes
is 40.35± 2.91%, which is lower than 46.32± 2.08 % of wild-type
Orlando and 46.77± 2.14% of AePUb>10miR mosquitoes, there
is no signiﬁcant difference among the three lines (Fisher’s exact
test: p = 0.17). We conclude that the high larval and pupal
mortality rate of AeCPA>10miR mosquitoes is not sex-
dependent. Male mating competitiveness of both transgenic lines
is determined by mating competition with the same number of
wild-type males. Our results show that the mating competitive-
ness of the AePUb>10miR male was 58.5± 7.8%, indicating an
advantage when compared with wild-type mosquitoes. For
AeCPA>10miR mosquitoes, the proportion of reporter-positive
mosquitoes was 26.3± 7.2%, supporting the conclusion that they
are less competitive in the presence of wild-type mosquitoes.
Mating competitiveness of the AePUb>10miR males was
signiﬁcantly higher compared to AeCPA>10miR males in the
presence of wild-type males (Fisher’s exact test: p = 0.004).
Virus suppression test of transgenic mosquitoes. The antiviral
efﬁciency of artiﬁcial miRNAs for each virus was conﬁrmed
separately for AePUb> 4miR:DENV3 and AePUb> 6miR:
CHIKV mosquitoes (Fig. 4, Supplementary Figure 3). These
mosquitoes were less capable of transmitting CHIKV at 6 days
post-infection (dpi) (Orlando (mean± SE): 27.08± 6.4, AePUb>
4miR:DENV3: 10.41± 4.45, AePUb> 6miR:CHIKV: 8.33± 4.03)
and DENV-3 at 21 dpi (Orlando: 27.08± 6.48, AePUb> 4miR:
DENV3: 0, AePUb> 6miR:CHIKV: 2.08± 2.06).
We then co-challenged two selected strains from AePUb>
10miR and AeCPA> 10miR mosquito lines with DENV-3 at 107
ffu/mL and CHIKV at 106 ffu/mL. Whole bodies, heads, and
saliva were collected for analyzing viral titers. Among
three groups of saliva collected from 24 AePUb>10miR and
AeCPA>10miR mosquitoes, the CHIKV transmission efﬁciency
was an average of 11.11% and 6.94%, respectively, at 6 dpi,
whereas the wild-type Orlando mosquitoes showed an average
transmission efﬁciency of 41.67% (Fig. 5, Supplementary
Figure 4).
CHIKV infection and dissemination barriers were assayed by
recovering virus particles from bodies and heads, and both AePUb
> 10miR and AeCPA> 10miR mosquitoes showed lower, but not
signiﬁcant, infection and dissemination rates (Fig. 5). The CHIKV
transmission-reducing phenotypes of the transgenic mosquitoes
were also conﬁrmed by a salivary glands using an immunoﬂuor-
escence assay. Salivary glands dissected at 6 dpi, reacted with
antibodies and visualized under ﬂuorescent microscope, showed
qualitatively lower signals in samples from each transgenic line
than wild-type Orlando mosquitoes (Supplementary Figure 5).
Anti-DENV-3 phenotypes tested at 21 dpi showed that the
infection rate, dissemination and transmission efﬁciencies of the
transgenic lines were signiﬁcantly lower than wild-type mosquitoes
(Fisher’s exact test: p< 10−4) (Fig. 5).
Table 1 Life-table parameters of transgenic mosquitoes
Mosquito
lines
Larval development
time (days)
Larval mortality
rate (%)
Pupal mortality
rate (%)
Adult lifespan
(days)
Sex ratio
(%)
Male mating
competitiveness (%)
Male Female Male Female
Orlando 6.43 ± 0.03 (307) 7.02±0.05
(265)
1.88± 0.56
(583)
2.83± 0.67
(600)
39.51 ± 11.58
(150)
44.32±
14.23 (150)
46.32±2.08
(572)
ND
AePUb>
10miR
6.12± 0.03 (289) 6.29± 0.03
(254)
4.40± 0.86
(568)
2.0± 0.57
(600)
36.9± 11.75
(150)
41.87±
14.91 (150)
46.77± 2.14
(543)
58.5± 15.8 (41)
AeCPA>
10miR
6.7 ± 0.04 (170) 6.87± 0.05
(115)
16.90± 2.02
(343)
7.75 ± 1.33
(400)
23.61 ± 10.0
(150)
28.15±
12.83 (150)
40.35 ± 2.91
(285)
26.3± 14.7 (38)
Mosquito larval development time, larval/pupal mortality, adult lifespan analysis, sex ratio, and test of male mating competitiveness were conducted at 28 °C. Larval developmental time was determined
by the period from the ﬁrst instar larva to pupal stage; Larval mortality corresponds to the number of emerged adults among analyzed larvae; Pupal mortality corresponds to the number of pupae among
emerged adults; Adult life spans were recorded daily by counting the number of dead mosquitoes and separated by sex; Proportion of females was determined by the number of females among all adults;
Male mating competitiveness was deﬁned as the proportion of reporter positive individuals compared to negative individuals in the same experimental cage. In brackets, the number of mosquitoes tested
is given
ND not determined
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Discussion
Against arboviruses, exogenous RNAi induced by long dsRNA
molecules is an effective mechanism to interrupt viral infection
and transmission46. Several studies have demonstrated the highly
effective antiviral siRNAs in genetically engineered mosquitoes.
For example, long dsRNAs (>500 bp in length) derived from
DENV-2, were processed into several siRNAs targeting the viral
genome and suppressed viral replication35,47. The high coverage
of the antiviral siRNAs on the viral genome provides a high level
of resistance against DENV-2 and reduces the risk of generating
siRNA escape variants. However, owing to the large diversity of
antiviral siRNAs produced, it is difﬁcult to predict regions tar-
geted in the mosquito transcriptome48. The effects of RNAi
machinery employing siRNA to suppress viral replication can be
transient as some viruses replicate so quickly that they overcome
the RNAi response49. These limitations can be surmounted using
hammerhead ribozymes. In cells and genetically engineered
mosquito experiments, the small catalytic hammerhead ribo-
zymes mediate a 15–16 nt sequence-speciﬁc cleavage and are
efﬁciently used as an antiviral effector against CHIKV, which
increases the range of possible target sites50. However, the error-
prone activities of RNA polymerase generate opportunities for
arboviruses to escape from ribozyme catalysis, which is only
triggered under high sequence speciﬁcity51,52. This deﬁciency can
be overcome by using antiviral group-I introns53,54 and by
targeting the conserved DENV and CHIKV sequences, which
then could lead to viral RNA trans-splicing and cell apoptosis. So
the resistance to arboviruses could be triggered by incomplete
viral RNA synthesis and cell death. Targeting the conserved viral
sequences can successfully increase the coverage of the four
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Fig. 4 Anti-DENV-3/CHIKV phenotype of transgenic 4miR:D3 and 6miR:
Chik mosquitoes. a Infection rate. b Dissemination rate. c Transmission
efﬁciency. Mosquitoes were co-challenged with DENV-3 Cambodia and
CHIKV 0621 strain at titer 107 and 106 ffu/mL, respectively. Samples were
collected and titrated at 6 and 21 dpi on C6/36 cells. The infection rate was
deﬁned as number of positive midgut samples of the total number tested;
dissemination efﬁciency was deﬁned as number of positive head samples of
the total number tested; transmission efﬁciency deﬁned as number of
positive saliva among number of tested. Saliva samples were collected via
salivation by inserting the proboscis of leg- and wing-less mosquito into a
P20 tip containing 5 microliter of FBS, then expelled into 45 microliter of L-
15 media after 30min for analysis. Each sample corresponds to two
replicates (2 × 24 mosquitoes) or 3 replicates (3 × 24 mosquitoes). The
error bars correspond to the conﬁdence intervals (95%). Signiﬁcant p
values are indicated by an asterisk: *p< 0.05, **p< 0.01, ***p< 0.001
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serotypes of DENV and CHIKV, without inducing signiﬁcant
ﬁtness impacts in naïve C6/36 cells. The antiviral activities of
group-I introns were initiated after recognition of several com-
ponents mediating RNA splicing, including internal guide
sequence, external guide sequence, and a helix forming sequences
(P10) on both viruses. However, the unknown mismatch toler-
ance of antiviral group-I introns might favor escape variants due
to the quasi-species nature of viral populations. Cell-based
experiments may not reﬂect the complexity of a mosquito
organism, so the ﬁtness impact needs to be examined carefully in
mosquitoes. In addition, the antiviral apoptotic cell death that is
triggered upon viral infection might result in different outcomes
depending on the virus. Apoptosis can suppress DENV replica-
tion but not SINV in mosquitoes55,56. Nevertheless, if a few
mismatches between the guide sequence and the target virus can
be tolerated, the antiviral group-I introns system in mosquitoes is
a potentially applicable molecular effector against arboviruses.
In this study, we generated several miRNA-based genetically
engineered mosquito lines with resistance to DENV-3 and
CHIKV triggered either ubiquitously or midgut speciﬁcally in
responding to a blood meal. The synthetic miRNAs we used were
22-nt in length, which are capable of targeting a broad range of
viral strains. Additionally, the predictable off-target effect of
antiviral miRNA provides tolerable features with mutant variants
that reduce the risk for the virus to escape from miRNA-mediated
silencing. In addition, the small sized synthetic miRNAs with
distinct targets can be easily assembled and transcribed as a
miRNA cluster, then processed into mature miRNAs through
endogenous miRNA pathway, without eliciting unintended
silencing resulting from siRNAs derived from long dsRNA.
Although the recipient mosquito strain Orlando was reported
as weakly susceptible to DENV-257, its vector competence
depends on the virus58. Orlando mosquitoes are still susceptible
to DENV-3 when provided at a viral titer of 1 × 107 ffu/mL.
Insertions of transgenes and their subsequent expression may
impose a load on the mosquitoes carrying them. This load could
result in a ﬁtness cost for the transgenic lines and may impair
their ability to be used in control strategies. There are several
previous reports of exogenous gene expression causing a variety
of effects on transgenic mosquitoes59,60. We observed a sig-
niﬁcant effect in AeCPA> 10miR compared to wild-type mos-
quitoes at immature and adult stages: longer larval development
time, higher larval and pupal mortalities, lower adult survival,
lower proportion of females at emergence and lower male mating
competitiveness. These effects may be caused by the strongly
expressed reporter DsRed in the AeCPA> 10miR mosquito line.
Nevertheless, AePUb> 10miR mosquitoes did not share the same
effects. In contrast, they had a shorter larval development time,
lower larval and pupal mortalities, higher adult survival, higher
proportion of females at emergence and higher male mating
competitiveness, all of which could facilitate vector control59.
Although a distinct result was observed between both mosquito
lines, we were not able to conclude that the AePUb> 10miR
construct has a lower ﬁtness impact to mosquitoes than the
AeCPA> 10miR construct, as they do not share the same
insertion site and this may cause some bias. The ﬁtness tests in
this study could only provide additional information for the two
selected lines carrying their distinct antiviral construct.
For testing the viral reduction phenotype under AePUb and
AeCPA induction strategies, we examined co-infected mosquitoes
with CHIKV at 6 dpi and DENV-3 at 21 dpi during the plateau
phase of viral replication in Ae. aegypti61. Saliva titers of DENV-3
and CHIKV were reduced in both transgenic mosquito lines;
however, viral infection and dissemination were not impaired
compared to wild-type mosquitoes. For CHIKV, although
transmission efﬁciencies were reduced in both transgenic lines,
AePUb> 10miR and AeCPA> 10miR mosquitoes showed a
lower but not signiﬁcant difference in infection rate and dis-
semination efﬁciency suggesting that only salivary glands but not
midguts behave as an efﬁcient barrier to the release of the virus in
saliva. In contrast, the transgenic mosquitoes showed more pro-
mising results on DENV-3 suppression than CHIKV when
examining infection, even though only four regions on DENV-3
were targeted by our anti-DENV-3 miRNAs.
It is likely that the anti-DENV-3 miRNAs have higher silencing
efﬁciency than anti-CHIKV miRNAs, or the expression levels of
anti-CHIKV miRNAs were not sufﬁcient to suppress CHIKV
characterized by a shorter extrinsic incubation period61–63. To
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Fig. 5 Anti-DENV-3/CHIKV phenotype of transgenic AePUb>10miR and
AeCPA>10miR mosquitoes. a Infection rate. b Dissemination rate. c
Transmission efﬁciency. Mosquitoes were co-challenged with DENV-3
Cambodia (Supporting information) and CHIKV 06.2171 strains at titers of
107 and 106 ffu/mL, respectively. Samples were collected and titrated at 6
and 21 dpi on C6/36 cells. Infection rate was deﬁned as number of positive
body samples among tested ones; dissemination efﬁciency refers to the
number of positive head samples (i.e., successful viral dissemination after
passing the midgut barrier) among tested ones; transmission efﬁciency was
deﬁned as the number of positive saliva (i.e., successful transmission)
among tested ones. Saliva samples were collected after 30min in a P20 tip
containing 5 µL of FBS and then expelled into 45 µl of L-15 media for
analysis. Each sample corresponds to 3 replicates (3 × 24 mosquitoes). The
error bars correspond to the conﬁdence intervals (95%). Signiﬁcant p
values are indicated by an asterisk: **p< 0.01, ***p< 0.001
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overcome this issue, replacing the miRNA targeting regions or
substituting the promoter with other high-activity promoters
would be a solution for optimizing the miRNA-based
mosquitoes64,65. In addition, the different expression patterns of
antiviral miRNAs might cause different viral reduction pheno-
types for each mosquito line. Although the characteristics of
Aedes PolyUbiquitin and Carboxypeptidase A gene promoters are
well studied66,67, the position of transgene integration also could
be important in determining antiviral potential68.
In summary, we successfully demonstrated the feasibility of
using artiﬁcial antiviral miRNAs to reduce the transmission of
two major arboviruses in transgenic Ae. aegypti. Although most
of the genetically engineered mosquito lines are still able to
transmit DENV-3 and CHIKV, the DENV-3 transmission rates
were reduced by 94.16% in AePUb> 10miR mosquitoes (from
23.61% to 1.38%), and the CHIKV transmission rates were
reduced by 77.33% (from 41.67% to 11.11%) and 83.35% (from
41.67% to 6.94%) in AePUb> 10miR and AeCPA> 10miR
mosquitoes, respectively. These reductions would greatly limit the
virus circulation. However, the effector has to be optimized to
approach 100% of viral suppression at midgut infection level,
eliminating the risk of virus dissemination. To apply these genes
in a population replacement strategy, they should be combined
with a gene-drive system, such as Cas9-mediated or toxin-
antidote underdominance gene drive system, by introgressing the
homozygous antiviral effector gene into target wild populations to
reduce disease transmission69,70. Therefore, maintaining high-
viral suppression efﬁciency with low ﬁtness impacts after com-
bining with mosquito gene drive system is needed. Thus, the
mosquitoes that we presented in this study are not yet applicable
in the ﬁeld and viral suppression at infection level should be
improved. For mosquitoes that are released in the ﬁeld, a “loca-
lized” transgenic line for control program is also needed. A local
mosquito strain must be used for mosquito transgenesis, to
reduce the alteration of the population’s gene pool. Therefore, the
ﬁtness issue of released mosquitoes should be analyzed again for
determining the replacement efﬁciency in the target population.
In this study, we have shown the potential of using synthetic
antiviral miRNAs as effector genes to combat multiple arbo-
viruses simultaneously. As the proof-of-concept has been vali-
dated, we can extend our strategy to other Aedes mosquito-borne
arboviruses such as YFV and ZIKV.
Methods
Plasmid DNA constructions. All the plasmids in this study were generated based
on the backbone of pMOS1_nanos-mimyd88_3xp3-CFP originated from Dr. Bruce
A. Hay (Caltech, CA), and re-modiﬁed by replacing the BglII site upstream of tub
3′ UTR with BamHI/XhoI sites (underlined) using PCR primers tub-3′UTR_
BamHI/XhoI-F and SV40-3′UTR_ NotI-R (Supplementary Table 4), generating
pMOS1_nanos-mimyd88_3xp3-CFP′. The anti-DENV-3 and anti-CHIKV miRNA
stem-loop backbones containing 5′-EcoRI/BglII and 3′-XhoI/BamHI were gener-
ated by oligo synthesis, and subcloned into pMOS1_nanos-mimyd88_3xp3-CFP
with EcoRI and XhoI sites, generating pMOS1_nanos-Den3-4miR_3xp3-CFP and
pMOS1_nanos-CHIKV-6miR_3xp3-CFP. The AePUb promoter was ampliﬁed
from Ae. aegypti genomic DNA by PCR primers pMOS1_fusion_FseI/PstIAePUb-
pr-F and pMOS1_fusion_BglII/EcoRIAePUb-pr-R, and subcloned into FseI and
EcoRI double digested pMOS1_nanos-Den3-4miR_3xp3-CFP and pMOS1_nanos-
CHIKV-6miR_3xp3-CFP with In-Fusion® HD Cloning technology (Clontech),
generating pMOS1_AePUb-Den3-4miR_3xp3-eGFP (GenBank accession:
MG603748)and pMOS1_AePUb-CHIKV-6miR_3xp3-eGFP (GenBank accession:
MG603749).
DENV-4miR was extracted from EcoRI and BamHI double digested
pMOS1_AePUb-Den3-4miR_3xp3-CFP, and CHIKV-6miR was extracted from
BglII and XhoI double digested pMOS1_AePUb-CHIKV-6miR_3xp3-CFP. The
two antiviral miRNA clusters were then subcloned into BglII and XhoII double
digested pMOS1_AePUb-Den3-4miR_3xp3-CFP, generating pMOS1_AePUb-
Den3-CHIKV-10miR_3xp3-eGFP (GenBank accession: MG603750). AeCPA
promoter was ampliﬁed from Ae. aegypti genomic DNA by PCR primers
pMOS1_fusion_FseI/PstIAeCPA-pr-F and pMOS1_fusion_BglII/EcoRIAeCPA-pr-
R, and then subcloned into FseI and EcoRI double digested pMOS1_AePUb-Den3-
CHIKV-10miR_3xp3-CFP, generating pMOS1_AeCPA-Den3-CHIKV-
10miR_3xp3-GFP. This plasmid was then re-modiﬁed by replacing the reporter
3xp3-CFP with BglII and XhoI sites (bolded) disrupted Hr5IE1-DsRed which
carried out by In-Fusion® HD Cloning technology with mutation primers
Oxitec_#4573_BglII-mutate-F and Oxitec_#4573_XhoI-mutate-R. By using In-
Fusion® HD Cloning technology with PCR primers pMOS1_fusion_Hr5IE1-
DsRed_marker_NotI-F and pMOS1_fusion_Hr5IE1-DsRed_marker_XmaI-R, the
Hr5IE1_DsRed was subcloned into NotI and XmaI double digested
pMOS1_AeCPA-Den3-CHIKV-10miR_3xp3-CFP, generating pMOS1_AeCPA-
Den3-CHIKV-10miR_Hr5IE1-DsRed (GenBank accession: MG603751).
miRNA off-target effect examination. The off-target effect of synthetic antiviral
miRNAs was predicted by using GESS (version 1.2) with the input parameters as
followed, 7 nt of siRNA seed sequence to test; Minimum 1 of seed matches to
consider an siRNA Seed Matching; Guide and Passenger strands were used for
analysis; P1C-seeds of active siRNAs as inactive siRNA seeds were used; All siRNA
seed sequences were scrambled as GESS control; No siRNA exclusion was allowed;
p-value 0.05 was set as signiﬁcance threshold parameter; Benjamini & Hochberg
False Discovery Rate was selected for testing correction.
Generation of transgenic mosquitoes. Ae. aegypti Orlando strain was used as the
recipient for germ-line transformation; the preblastoderm embryos were injected
with the mixture of donor and helper plasmids at a ratio of 300:500 ng/µL in
injection buffer (5 mM KCl and 0.1 mM NaH2PO4, pH 6.8). Mosquitoes were
reared at 28 °C, 70% relative humidity, and a 12:12 light/dark regime and fed ad
libitum with a 10% sucrose solution.
Embryo microinjection was carried out as described in Lobo et al.44. Each
surviving G0 male adult was outcrossed with 3 wild-type females, G0 females were
pooled together and crossed with wild-type males at a male/female ratio 1:3. All the
eggs collection and G1 larvae screening were carried out individually. G1 larvae
were screening for reporter gene expression under a ﬂuorescent microscope
(LeicaMZ12.5, Wetzlar, Germany). The transgenic G1 mosquitoes were then
outcrossed with wild-type mosquitoes for one generation to conﬁrm the Mendelian
inheritance in progenies. To establish homozygous lines, the transgenic mosquitoes
were inter-crossed individually and the homozygous candidates were screened for
two generations.
Mosquito experimental infections. Seven-day-old female adults were fed on
artiﬁcial infectious blood meal containing 1.4 mL of washed rabbit red blood cells
and 0.7 mL of virus infected C6/36 cells suspension. The blood meal was supple-
mented with ATP as a phagostimulant at a ﬁnal concentration of 1 mM and
provided to mosquitoes using a Hemotek membrane feeding system. Virus titers of
the artiﬁcial infectious blood meal were at 106 and 107 ffu/mL for CHIKV and
DENV respectively. Engorged mosquitoes were transferred into cardboard con-
tainers and maintained with 10% sucrose under a photoperiod of 12:12, at
28 °C. Mosquito saliva was collected using the forced salivation technique described
in Dubrulle et al. (2009)61. After removing mosquito wings and legs, the proboscis
was inserted into P20 tips ﬁlled with 5 µL of fetal bovine serum (FBS). After 30 min,
saliva was expelled from the tip to 45 µL of L-15 medium. After salivation, mos-
quito head and body were collected and grounded individually in 300 µL of L-15
medium supplemented with 2% FBS. In total 200 µL of homogenates were collected
for titration after centrifugation at 10,000 × g for 5 min.
Mosquitoes were examined at 6 dpi when infected with CHIKV and 21 dpi with
DENV-3. Infection rate (IR) refers to the proportion of mosquitoes with infected
body among engorged mosquitoes. Dissemination efﬁciency (DE) corresponds to
the proportion of mosquitoes with infected head among mosquitoes with infected
body. Transmission efﬁciency (TE) represents the proportion of mosquitoes with
infectious saliva among mosquitoes examined.
Mosquitoes screening test. To avoid any bias caused by the position effect of
integration on antiviral efﬁciency, a mosquito screening test was conducted with
three independent lines of AePUb> 10miR and ﬁve independent lines of AeCPA
> 10miR mosquitoes (Supplementary Table 2), and the virus transmission efﬁ-
ciency was analyzed to select the mosquito lines that exhibited the strongest
antiviral phenotype for each construct (Supplementary Figure 6). Mosquitoes were
co-challenged with both DENV-3 and CHIKV as described above, and the saliva
were collected at 6 and 14 dpi for analyzing virus transmission efﬁciency. The two
selected lines for each antiviral construct were used for further analysis.
Southern blot analysis. In total 20 µg of genomic DNA was produced and
digested with restriction enzymes BglII or ScaI, followed by DNA separation on
0.8% agarose gel. The separated DNA was then transferred onto a nylon membrane
and hybridized with random-primed [α32P] dCTP-labeled DNA probes com-
plementary to the 10miRNA clusters at 42 °C for 16 h. No restriction enzyme site of
ScaI was present in the transgene and only one BglII site was present in the
upstream of miRNA cluster, which makes the expected size of hybridization pat-
terns»6698 bp and >>7591 bp for ScaI; >>4927 bp and >>6079 bp for BglII
digested AePUb> 10miR and AeCPA> 10miR mosquitoes, respectively.
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Virus detection in salivary glands. The viral particles of CHIKV were detected in
mosquito salivary glands by immunoﬂuorescence assay. Salivary glands were dis-
sected in PBS and ﬁxed with 4% paraformadehyde at 6 and 21 dpi, followed by
hybridization with anti-CHIKV antibodies respectively. After exposing to sec-
ondary antibodies, tissues were transferred on a slide with mounting solution
(ProLong® Gold Antifade Mountant). The infection patterns were visualized under
ﬂuorescent microscope. DAPI was used for cell localization.
Life-table parameters of transgenic mosquitoes. Seven-day old eggs were
vacuum hatched to synchronize the rearing process. Newly hatched larvae were
counted and reared in daily renewed 1 L of water with 1 yeast tablet. Larvae were
checked daily until pupation and adult emergence. In total 50 adults of each sex from
the same batch of mosquitoes were pooled together and maintained on 10% sucrose
for adult lifespan analysis. For mating competitiveness test, 20 virgin females of wild-
type mosquitoes were grouped with 10 wild-type males and 10 transgenic males.
Mosquitoes were fed on blood meal at 7 days after being grouped up, and eggs were
collected from each female on 4 days after blood meal. All mosquitoes were reared at
28 °C and 70% in relative humidity with a photoperiod of 12:12.
Artiﬁcial miRNA expression analysis. Mosquito small RNA was extracted from
the midguts and carcasses of sugar fed and 24 hPBM mosquitoes. Tissues were
lysed in Trizol solution and total RNA was precipitated with 75% ethanol (v/v).
Total RNA was used for miRNA cDNA synthesis by MystiCqTM microRNA cDNA
Synthesis Mix (Sigma-Aldrich), whereas qPCRs were performed using Mys-
tiCq®microRNA®SYBR® Green qPCR Ready MixTM (Sigma-Aldrich) on Applied
Biosystems 7500 Fast. Primer sequences are included in Supplementary Table 3.
aae-miR-1 is one of the most highly and relatively stably expressed miRNA in Ae.
aegypti and was used as an internal control for detecting miRNAs expression in this
study. Because artiﬁcial miRNAs were not expressed in wild-type mosquitoes, data
were normalized twice to each aae-miR-1 and wild-type aae-miR-1 presenting the
relative expression proﬁle.
Statistical analysis. All statistical tests were conducted using the STATA software
(StataCorp LP, Texas, USA). Proportions were compared using Fisher’s exact test
and sample distributions with the Kruskal–Wallis test. P-values>0.05 were
considered non-signiﬁcant.
Data availability. All data generated or analyzed during this study are included in
this published article (and its supplementary information ﬁles). The accession
codes of the plasmid sequences are MG603748 (pMOS1_AePUb-Den3-
4miR_3xp3-eGFP), MG603749 (pMOS1_AePUb-CHIKV-6miR_3xp3-eGFP),
MG603750 (pMOS1_AePUb-Den3-CHIKV-10miR_3xp3-eGFP) and MG603751
(pMOS1_AeCPA-Den3-CHIKV-10miR_Hr5IE1-DsRe).
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